MonoSol Rx is developing a portfolio of film formulations for existing prescription drugs. Targets are selected based upon technical suitability for the Company’s PharmFilm® drug delivery technology, patent expiration, approved indications, market size and other factors. MonoSol Rx’s objective is to maximize the commercial value of these drugs by seeking to partner with drug innovators to enable them to extend the revenue life cycle of their prescription drugs. This strategy significantly reduces development risk and cost. Because MonoSol Rx’s products are reformulations of already approved chemical entities, the Company also benefits from accelerated regulatory timelines to approval.